

Practitioner's Docket No. MPI00-633P1RM

USSN 09/939,853

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. – 4. (Canceled)

5. (Currently Amended) An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:

- (a) a mature form of SEQ ID NO:75; and
- (b) ~~a variant of a mature form of SEQ ID NO:75, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;~~
- (c) ~~SEQ ID NO:75; and~~
- (d) ~~a variant of SEQ ID NO:75, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;~~

or a nucleic acid molecule comprising the complement of the nucleic acid molecule encoding the polypeptide of (a), ~~(b), (c), or (d)~~ or (b).

6. – 7. (Canceled)

8. (Previously Presented) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule differs by a single nucleotide from a nucleic acid sequence selected from the group consisting of SEQ ID NOS: 74 and 76.

9. (Currently Amended) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

- (a) a nucleotide sequence selected from the group consisting of SEQ ID NOS: 74 and 76;
- (b) a nucleotide sequence differing by one or more nucleotides from a nucleotide sequence selected from the group consisting of SEQ ID NOS: 74 and 76, provided

(Page 4 of 13)

Practitioner's Docket No. MPI00-633P1RM

USSN 09/939,853

that no more than ~~20%~~ 5% of the nucleotides differ from said nucleotide sequence; and

(c) the ORF of SEQ ID NO:74.

10. (Previously Presented) The nucleic acid molecule of claim 5, wherein said nucleic acid molecule hybridizes under stringent conditions to a nucleotide sequence chosen from the group consisting of SEQ ID NOS:74 and 76, or a complement of said nucleotide sequence.

11. (Currently Amended) The nucleic acid molecule of claim 5, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

- (a) a first nucleotide sequence comprising a coding sequence differing by one or more nucleotide sequences from a coding sequence encoding said amino acid sequence, provided that no more than ~~20%~~ 5% of the nucleotides in the coding sequence in said first nucleotide sequence differ from said coding sequence; and
- (b) an isolated second polynucleotide that is a complement of the first polynucleotide.

12. (Original) A vector comprising the nucleic acid molecule of claim 11.

13. (Original) The vector of claim 12, further comprising a promoter operably-linked to said nucleic acid molecule.

14. (Original) A cell comprising the vector of claim 12.

15. – 18. (Canceled)

19. (Original) A method for determining the presence or amount of the nucleic acid molecule of claim 5 in a sample, the method comprising:

- (a) providing the sample;
- (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
- (c) determining the presence or amount of the probe bound to said nucleic acid molecule,

thereby determining the presence or amount of the nucleic acid molecule in said sample.

(Page 5 of 13)

**Practitioner's Docket No. MPI00-633P1RM****USSN 09/939,853**

20. (Original) The method of claim 19 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
21. (Original) The method of claim 20 wherein the cell or tissue type is cancerous.
22. – 38. (Canceled)
39. (Original) A pharmaceutical composition comprising the nucleic acid molecule of claim 5 and a pharmaceutically-acceptable carrier.
40. – 41. (Canceled)
42. (Original) A kit comprising in one or more containers, the pharmaceutical composition of claim 39.
43. – 45. (Canceled)
46. (Original) A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 5 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
  - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
47. (Original) The method of claim 46 wherein the predisposition is to a cancer.
48. – 49. (Canceled)

(Page 6 of 13)

Practitioner's Docket No. MPI00-633P1RM

USSN 09/939,853

50. (Previously Presented) The method of claim 20 wherein the cell or tissue type is from an immune-mediated disease.

51. (Previously Presented) The method of claim 46 wherein the predisposition is to an immune-mediated disease.

52. (Currently Amended) An isolated nucleic acid molecule selected from the group consisting of:

- a) a nucleic acid molecule comprising ~~a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:74, wherein said nucleic acid molecule encodes a polypeptide having a protein tyrosine kinase-like activity;~~
- b) a nucleic acid molecule comprising the ORF of SEQ ID NO:74; and
- c) a nucleic acid molecule consisting of an oligonucleotide of at least 15 contiguous nucleotides of the nucleotide sequence of SEQ ID NO:74 or SEQ ID NO:76, or a complement thereof.

53. (Currently Amended) The nucleic acid molecule of claim 52, wherein the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of:

- a) SEQ ID NO:74;
- b) SEQ ID NO:76; and
- c) the ORF of SEQ ID NO:74~~SEQ ID NO:140;~~
- ~~d) SEQ ID NO:141; and~~
- ~~e) SEQ ID NO:142.~~

54. (Previously Presented) A method for determining the presence or amount of the nucleic acid molecule of claim 52 in a sample, the method comprising:

- (a) providing the sample;
- (b) contacting the sample with a probe that binds to said nucleic acid molecule; and
- (c) determining the presence or amount of the probe bound to said nucleic acid molecule,

thereby determining the presence or amount of the nucleic acid molecule in said sample.

(Page 7 of 13)

**Practitioner's Docket No. MPI00-633P1RM****USSN 09/939,853**

55. (Previously Presented) The method of claim 54 wherein presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.
56. (Previously Presented) The method of claim 55 wherein the cell or tissue type is cancerous.
57. (Previously Presented) The method of claim 55 wherein the cell or tissue type is from an immune-mediated disease.
58. (Previously Presented) A method for determining the presence of or predisposition to a disease associated with altered levels of the nucleic acid molecule of claim 52 in a first mammalian subject, the method comprising:
- (a) measuring the amount of the nucleic acid in a sample from the first mammalian subject; and
  - (b) comparing the amount of said nucleic acid in the sample of step (a) to the amount of the nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease;
- wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.
59. (Previously Presented) The method of claim 58 wherein the predisposition is to a cancer.
60. (Previously Presented) The method of claim 58 wherein the predisposition is to an immune-mediated disease.
61. (Previously Presented) A vector comprising the nucleic acid molecule of claim 5.
62. (Previously Presented) The vector of claim 61, further comprising a promoter operably-linked to said nucleic acid molecule.
63. (Previously Presented) A cell comprising the vector of claim 61.

(Page 8 of 13)

**Practitioner's Docket No. MPI00-633P1RM****USSN 09/939,853**

64. (Previously Presented) A cell which expresses the nucleic acid molecule of claim 5.
65. (Previously Presented) A vector comprising the nucleic acid molecule of claim 52.
66. (Previously Presented) The vector of claim 65, further comprising a promoter operably-linked to said nucleic acid molecule.
67. (Previously Presented) A cell comprising the vector of claim 65.
68. (Previously Presented) A cell which expresses the nucleic acid molecule of claim 52.
69. (Previously Presented) A pharmaceutical composition comprising the nucleic acid molecule of claim 52 and a pharmaceutically-acceptable carrier.
70. (Previously Presented) A kit comprising in one or more containers, the pharmaceutical composition of claim 69.
71. (Previously Presented) A nucleic acid molecule consisting of a nucleotide sequence selected from the group consisting of:
- a) SEQ ID NO:74;
  - b) SEQ ID NO:76;
  - c) the ORF of SEQ ID NO:74;
  - d) SEQ ID NO:140;
  - e) SEQ ID NO:141; and
  - f) SEQ ID NO:142.
72. (New) The method of claim 19, wherein the probe is a nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:74, SEQ ID NO:76, or a complement thereof.
73. (New) The method of claim 54, wherein the probe is selected from the group consisting of:

(Page 9 of 13)

Practitioner's Docket No. MPI00-633P1RM

USSN 09/939,853

- a) SEQ ID NO:140;
- b) SEQ ID NO:141;
- c) SEQ ID NO:142; and
- d) the ORF of SEQ ID NO:74, or a complement thereof.

(Page 10 of 13)